Journal of Clinical Apheresis最新文献

{"title":"Mapping the Scientific Landscape of Therapeutic Apheresis: The First Comprehensive Bibliometric and Science Mapping Analysis.","authors":"Joan Cid, Paola Charry, Alexandra Pedraza, Miquel Lozano","doi":"10.1002/jca.70196","DOIUrl":"https://doi.org/10.1002/jca.70196","url":null,"abstract":"<p><p>Bibliometrics is the quantitative analysis of written publications. Despite the growing clinical and scientific importance of therapeutic apheresis, a comprehensive bibliometric evaluation of the field has not previously been performed. This study aimed to assess the development, collaboration patterns, citation impact, and intellectual structure of therapeutic apheresis research. A descriptive bibliometric study was conducted using PubMed, Scopus, and Web of Science Core Collection (WoS) databases. Data were retrieved on July 31, 2026. The search strategy was based on therapeutic apheresis procedures according to guidelines published by the American Society for Apheresis (ASFA). Performance analysis and science mapping were applied. VOSviewer was used for network construction and visualization. A total of 11859, 4706, and 2888 publications were identified in PubMed, Scopus, and WoS, respectively. A high degree of collaboration was observed, with > 80% of publications being multiauthored and > 80% receiving at least one citation. Average citations per publication ranged from 15.15 to 18.83. The Scopus dataset achieved an h-index of 110 and included 45 publications cited at least 200 times. Journal of Clinical Apheresis emerged as the dominant journal in both Scopus and WoS. The cocitation analysis identified 1694 cited references receiving ≥ 5 citations. The most influential references were clinical guidelines and consensus recommendations for clinical practice. Therapeutic apheresis research has evolved into a mature, multidisciplinary, and highly collaborative scientific field. As the first comprehensive bibliometric analysis of apheresis research, this study establishes a benchmark against which future advances in the field can be measured.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":"e70196"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Plasma Exchange in a Pediatric Lupus-Associated Thrombotic Microangiopathy: Prolonged Treatment Guided by Serial Biomarker Response.","authors":"Rituparna Bhattacharya, Karan Kumar, Subhankar Sarkar, P Shabeel, Priyadarsini Jayachandran Arcot","doi":"10.1002/jca.70197","DOIUrl":"https://doi.org/10.1002/jca.70197","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs including kidney. Class IV lupus nephritis is the most severe form and sometimes complicated by thrombotic microangiopathy (TMA), leading to microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury (AKI). We report a 9-year-old female diagnosed with Class IV lupus nephritis complicated by TMA, severe AKI, and resistant hypertension. Therapeutic plasma exchange (TPE) was initiated as an adjunctive therapy due to clinical severity. A total of 15 TPE sessions were performed over 4 weeks. Serial monitoring showed improvement in hematologic parameters, renal function, and clinical status. At 8-month follow-up, the patient maintained clinical and renal remission without relapse. This case highlights the role of prolonged, response-guided TPE in severe lupus-associated TMA in resource-poor settings where complement-targeted therapies are not available.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apheresis-Triggered Torsades De Pointes in Congenital Long QT Syndrome Type 2: Citrate-Related Arrhythmia Risk and Safe Modality Switching During Myasthenic Crisis","authors":"Masahiro Biyajima,&nbsp;Yusuke Nakamura,&nbsp;Toshihiro Nagaoka,&nbsp;Ko-Ichi Tazawa","doi":"10.1002/jca.70185","DOIUrl":"10.1002/jca.70185","url":null,"abstract":"<div>\u0000 \u0000 <p>Citrate anticoagulation during therapeutic plasma exchange (TPE) chelates divalent cations and can precipitate torsades de pointes (TdP) in patients with pre-existing repolarization vulnerability. We report a 44-year-old woman with genetically determined long QT syndrome Type 2 (LQT2) presenting in myasthenic crisis due to anti-MuSK-positive myasthenia gravis. TPE was initiated urgently before confirmatory antibody results were available, as alternative rapid immunomodulatory options were not immediately accessible. Despite prophylactic electrolyte supplementation, the corrected QT interval (QTc) progressively prolonged, rising from a baseline of 493 to 509 ms—exceeding the 500 ms high-risk threshold—immediately before TdP onset during the second TPE. TPE was discontinued and replaced with double-filtration plasmapheresis (DFPP) using albumin-based replacement, which reduces citrate exposure by retaining the patient's own albumin. Five subsequent DFPP sessions were completed without arrhythmia recurrence. This case highlights the apheresis-related arrhythmia risk in LQT2 and the mechanistic rationale for DFPP as a safer alternative.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fractionated Intermediate-Dose Etoposide Plus G-CSF for Peripheral Blood Stem Cell Mobilization in Patients With Lymphoma and Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Prospective Observational Study","authors":"Yoo Jin Lee,&nbsp;Sang Hyuk Park,&nbsp;Youjin Kim,&nbsp;Ji-Hun Lim,&nbsp;Hyun-Ki Kim,&nbsp;HeeJung Cha,&nbsp;Jae-Cheol Jo","doi":"10.1002/jca.70183","DOIUrl":"10.1002/jca.70183","url":null,"abstract":"<div>\u0000 \u0000 <p>Efficient and safe mobilization of peripheral blood CD34⁺ stem cells is essential for successful autologous stem cell transplantation (ASCT) in patients with lymphoid malignancies. However, current mobilization strategies are often limited by suboptimal yield, significant toxicity, or high cost. We conducted a prospective observational study including 59 patients with lymphoma or multiple myeloma undergoing ASCT. Patients received fractionated intermediate-dose etoposide (175 mg/m² twice on days 1 and 2) followed by granulocyte colony-stimulating factor (G-CSF, 10 μg/kg daily). Mobilization efficacy, safety profile, and subsequent transplantation outcomes were evaluated. Successful mobilization (≥ 2 × 10⁶ CD34+ cells/kg) was achieved in 96.6% of patients within three days of apheresis. The median CD34⁺ cell yield was 5.35 × 10⁶ CD34+ cells/kg on the first day. Notably, 61.0% and 49.2% of patients collected ≥ 4 × 10⁶ and ≥ 6 × 10⁶ CD34⁺ cells/kg on the first day, respectively. Despite frequent grade 3–4 cytopenias, clinically significant complications were limited, with febrile neutropenia occurring in 16.9% of patients and no treatment-related mortality (TRM). All patients achieved neutrophil and platelet engraftment. Fractionated intermediate-dose etoposide combined with G-CSF achieved a high mobilization success rate, with most patients requiring a limited number of apheresis sessions and no TRM.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Exchange for Hantavirus Pulmonary Syndrome: A Mechanistic Case for an Untested Intervention","authors":"Menatalla Nadim,&nbsp;Yasamin Mirzabeigi,&nbsp;Yamac Akgun","doi":"10.1002/jca.70187","DOIUrl":"10.1002/jca.70187","url":null,"abstract":"<p>Hantavirus pulmonary syndrome (HPS) carries a case fatality rate of 35%–40% and has no approved pharmacologic treatment. Its pathophysiology is rooted in the plasma compartment: cytokines, viral antigens, immune complexes, and platelet-binding glycoproteins circulate as drivers of immunopathologic endothelial injury, noncardiogenic pulmonary edema, and cardiogenic depression. Therapeutic plasma exchange (TPE) achieves bulk clearance of plasma-borne mediators and is established by the American Society for Apheresis (ASFA) for numerous indications that share an analogous mechanistic rationale. This commentary argues that the immunopathology of HPS maps onto the therapeutic targets of TPE, that any intervention would need to be timed to the early cardiopulmonary phase, and that the coagulopathic dimension of the disease provides a mechanistic argument for incorporating plasma into the replacement strategy. We deliberately situate this rationale against the uneven record of TPE in diseases of comparable pathophysiology, in which the intervention has been effective in some settings and without demonstrable benefit in others. The recent Andes virus outbreak aboard the cruise ship MV Hondius, which produced a multinational cluster of severe cardiopulmonary cases, prompted us, as transfusion medicine and apheresis physicians, to articulate this hypothesis. We emphasize that these arguments are mechanistic and hypothesis-generating rather than evidence-based: no clinical data yet support TPE in HPS, and systematic outcome reporting, ideally through a multicenter case series, would be required before any conclusion about efficacy could be drawn.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Citrate Reaction Grading and Treatment Chart for Patients Undergoing Leukapheresis Procedures","authors":"Amber Lebron,&nbsp;Hanna Bailey,&nbsp;Tina M. Mason,&nbsp;Darling Nelcy,&nbsp;Shantrell Jones,&nbsp;Serena Hamelin,&nbsp;Hien D. Liu","doi":"10.1002/jca.70182","DOIUrl":"https://doi.org/10.1002/jca.70182","url":null,"abstract":"<div>\u0000 \u0000 <p>Calcium supplementation to prevent or treat hypocalcemic symptoms during leukapheresis is not standardized. Institutions vary in practice. Within an institution, there is also nursing variability. Recognizing the need to harmonize our practices, the apheresis nurses at our institution launched a process improvement initiative to develop a standardized Citrate Reaction Grading and Treatment Chart for leukapheresis procedures. Based on nurse surveys, interdisciplinary collaboration, and clinical data, the chart enhances recognition and management of hypocalcemia-related symptoms, aiming to improve patient safety and streamline care across apheresis practices.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caution in the Bag: A Sheet-Like Deposit as a Visual Clue to Systemic Derangement in Immune-Mediated TTP","authors":"Taniya Kapoor,&nbsp;Sathish Saravanan,&nbsp;Durga Shankar Meena,&nbsp;Parmatma Prasad Tripathi,&nbsp;Siddharth Mittal","doi":"10.1002/jca.70181","DOIUrl":"10.1002/jca.70181","url":null,"abstract":"","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Double-Filtration Plasmapheresis Versus Efgartigimod in Generalized Myasthenia Gravis: A Single-Center Retrospective Study","authors":"Jingwen Li,&nbsp;Wenbin Wan,&nbsp;Jun Wu,&nbsp;Yufang Mei,&nbsp;Liping Ni,&nbsp;Huiying Qiu,&nbsp;Yan Zhou,&nbsp;Ying Zhang,&nbsp;Bei Zhang,&nbsp;Gang Wang,&nbsp;Yunlan Du,&nbsp;Jieli Geng","doi":"10.1002/jca.70176","DOIUrl":"10.1002/jca.70176","url":null,"abstract":"<div>\u0000 \u0000 <p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating muscle weakness. Double-filtration plasmapheresis (DFPP) and efgartigimod are commonly used therapeutic strategies for patients with generalized MG (gMG). This single-center retrospective study aimed to evaluate and compare the efficacy and safety of DFPP and efgartigimod in the management of gMG. We retrospectively reviewed clinical records of gMG patients who received either DFPP or efgartigimod at our hospital. This was not a crossover study, and no patient received both treatments during the study period. Collected data included demographic and clinical characteristics, antibody titers, Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, Quantitative Myasthenia Gravis (QMG) scores, and treatment-related adverse events. Immunoglobulin and antibody levels before and after therapy were analyzed to assess treatment responses. A total of 31 patients with gMG were included, comprising 17 who underwent DFPP and 14 who received efgartigimod. The participants ranged from 25 to 79 years of age, and 74.2% were female. Anti-acetylcholine receptor antibodies were detected in 25 patients. Both DFPP and efgartigimod significantly reduced immunoglobulin and pathogenic antibody levels and improved MG-ADL and QMG scores. Between-group differences in the observed short-term changes were not statistically significant. Mild adverse events, including catheter-site bleeding and transient limb weakness, occurred in the DFPP group, whereas no adverse events were reported among efgartigimod-treated patients. Both DFPP and efgartigimod effectively reduced antibody levels and improved clinical symptoms in patients with gMG after a single treatment course. Efgartigimod showed favorable tolerability in this cohort, although this finding should be interpreted cautiously given the small sample size and retrospective design.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue","authors":"Nicole D. Zantek,&nbsp;Caroline R. Alquist,&nbsp;Jan C. Hofmann,&nbsp;Reinhard Klingel,&nbsp;Yosef Levenbrown,&nbsp;Oluwatoyosi A. Onwuemene,&nbsp;Gopal Patidar,&nbsp;Christopher J. Patriquin,&nbsp;Jay S. Raval,&nbsp;Amber P. Sanchez,&nbsp;Jennifer Schneiderman,&nbsp;Yvette C. Tanhehco,&nbsp;Laura Connelly-Smith","doi":"10.1002/jca.70141","DOIUrl":"https://doi.org/10.1002/jca.70141","url":null,"abstract":"<div>\u0000 \u0000 <p>The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis (TA) in human disease. As in recent editions, the Tenth Edition of the JCA Special Issue committee has incorporated systematic review and evidence-based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Tenth Edition comprises 93 fact sheets and 183 graded and categorized indications. This includes two new fact sheets and several changes to indications, categorization, or grade on existing fact sheets. The Tenth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 S2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148974946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-Dependent Decline in Extraction Ratios for LDL Cholesterol and Fibrinogen During a Single Rheocarna Treatment Session","authors":"Masayoshi Kukida,&nbsp;Itsuki Miyake,&nbsp;Sayaka Ito,&nbsp;Fumikazu Kondo,&nbsp;Satoru Shichijo,&nbsp;Daiki Hirakawa,&nbsp;Bunya Yamada,&nbsp;Tsutomu Mima,&nbsp;Osamu Yamaguchi","doi":"10.1002/jca.70179","DOIUrl":"10.1002/jca.70179","url":null,"abstract":"<div>\u0000 \u0000 <p>Lipoprotein apheresis is an adjunctive treatment for severe peripheral artery disease (PAD) and is a Category II indication for peripheral vascular diseases in the American Society for Apheresis guidelines. Rheocarna, a direct hemoperfusion adsorption device used in Japan for severe PAD and chronic limb-threatening ischemia (CLTI), is designed to remove LDL cholesterol (LDL-C) and fibrinogen (Fib). Device performance is often summarized by pre−/post-treatment values or a single-point extraction ratio (ER), which may not capture time-dependent changes in adsorption efficiency. We therefore characterized serial ER profiles during Rheocarna treatment in maintenance hemodialysis patients with severe CLTI (5 patients, 10 sessions) and in a closed-loop ex vivo system using pooled plasma. Inlet and outlet samples were obtained serially, and ER was calculated as (<i>C</i>_in − <i>C</i>_out)/<i>C</i>_in × 100. In clinical sessions, median LDL-C ER declined from 73.7% (IQR 70.9–76.2) at baseline to 12.3% (10.3–14.6) at 60 min and 5.2% (3.1–8.2) at 120 min (<i>p</i> &lt; 0.0001). Fib ER similarly declined from 63.3% (59.9–69.9) at baseline to 7.9% (6.2–10.1) at 60 min and 6.5% (5.1–7.5) at 120 min (<i>p</i> &lt; 0.0001). In the ex vivo system, LDL-C ER also decreased over time (<i>p</i> = 0.0274), whereas Fib ER showed a more variable pattern (<i>p</i> = 0.1877). These findings show that extraction efficiency changes substantially during a treatment session and may not be fully captured by a single-point ER. Serial ER profiling may provide a more detailed assessment of the time-dependent performance of adsorption-based apheresis devices.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"41 5","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}